Abcuro, Inc. is a biotechnology company developing therapies for autoimmune diseases and cancer, with a focus on their lead candidate, ulviprubart, a monoclonal antibody for treating inclusion body myositis.

Aviceda Therapeutics is a biotech company developing next-generation immunomodulators for ophthalmic conditions using its proprietary HALOS™ nanotechnology platform.

Nuvig Therapeutics is a biotechnology company developing treatments for autoimmune diseases that do not rely on immunosuppression.

Alpha-9 Oncology Inc. develops targeted radiopharmaceuticals to improve cancer treatment.

Radiant Biotherapeutics develops innovative therapies using its proprietary Multabody™ platform to target oncology, inflammation, immunology, and infectious diseases.